Imunon Inc (IMNN) progresses with pivotal Phase 3 trials while navigating financial hurdles and seeking strategic ...

Stacy Lindborg; President, Chief Executive Officer and Board Director; Imunon Inc. Presentation. Operator. Good morning. My name is Dave, and I will be your operator ...

That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...

Imunon Inc (IMNN) reported a narrower-than-expected loss for the first quarter of 2025, with earnings per share (EPS) of -$0.28 against a forecast of -$0.3575. The company’s stock price responded ...